Journal of Vaccines & Vaccination

The provocative issue of tumor genomic heterogeneity in immunotherapy

9^th Global Summit and Expo on Vaccines & Vaccination

November 30-December 02, 2015 San Francisco, USA

Michael G Hanna

Vaccinogen Inc., USA

Posters-Accepted Abstracts: J Vaccines & Vaccin

Abstract:

While it has always been presumed that neoplasia is a consequence of somatic cell mutations, only in the last few years, the magnitude and diversity of these mutations has been elucidated by modern DNA sequencing technology. Immunotherapy is the premier biological approach to targeted therapy. Target therapies require targets. In this case, the targets are tumor specific or associated antigens, the proteins expressed from these somatic cell mutations. While the immunotherapeutic approach to eliminating cancer was launched with the assumption that cancer cells were homogeneous, the recent genomic understanding of tumor cells indicates that there is both inter and intra-tumoral heterogeneity. This presentation will discuss the consequences of this new knowledge of tumor cell biology to the immunotherapeutic approach to treating cancer. What is more, this presentation will discuss the translational development of an active specific immunotherapeutic approach from preclinical to beneficial clinical benefits.

Biography :

Email: mghannajr@vaccinogeninc.com